Drug
Aficamten clinical trials
Also written CK-3773274.
- studies test it
- 12
- open now
- 2
- in phase 3
- 7
- first study started
- 2018
Keep track of what changes. Save the aficamten studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
12 studies that test it; most in 2023 (4)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 3
- Phase 3
- 7
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 1
Cytokinetics (8) · Corxel Pharmaceuticals (2) · Bayer (1) · Oregon Health and Science University (1)
Studies
Open first, then newest update. How each study uses aficamten is read from its arms, and is right about nine times in ten.
Testing it · 12
- Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCMEnrolling by invitationPhase 2/3CytokineticsNCT04848506Written as Aficamten (5 - 20 mg)
- Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic CardiomyopathyRecruitingPhase 4Oregon Health and Science UniversityNCT07600177Written as Aficamten
- A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic CardiomyopathyActive, not recruitingPhase 3BayerNCT07023341Written as BAY3723113
- A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)Active, not recruitingPhase 3CytokineticsNCT06081894Written as Aficamten
- A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).Active, not recruitingPhase 2/3CytokineticsNCT06412666Written as Aficamten
- Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCMCompletedPhase 3CytokineticsNCT05767346Written as Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)
- Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCMCompletedPhase 3CytokineticsNCT05186818Written as Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)
- Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic CardiomyopathyCompletedPhase 2CytokineticsNCT04219826Written as CK-3773274 (5 - 15 mg)
- An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCMCompletedPhase 3Corxel PharmaceuticalsNCT06116968Written as Aficamten
- Safety, Tolerability and Pharmacokinetics Study of CK-3773274CompletedPhase 1Corxel PharmaceuticalsNCT04783766Written as CK-3773274
- A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult SubjectsCompletedPhase 1CytokineticsNCT03767855Written as CK-3773274 - Granules in Capsule
- Study to Evaluate the Effect of Aficamten Administration on QT/QTc IntervalCompletedPhase 1CytokineticsNCT05924815Written as Aficamten
Codes
What other systems call aficamten · ClinicalTrials.gg INT002121
- MeSH (NLM) C000731669aficamtenOne source NLM
- UNII (FDA) B1I77MH6K1AFICAMTENConfirmed FDA, NLM, Wikidata
- Wikidata Q106438207aficamtenConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C179072AficamtenOne source FDA
- DrugBank DB18490One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731669 | aficamten | One source NLM |
| UNII (FDA) | B1I77MH6K1 | AFICAMTEN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q106438207 | aficamten | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C179072 | Aficamten | One source FDA |
| DrugBank | DB18490 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.